Analysts have been eager to weigh in on the Healthcare sector with new ratings on Abbott Labs (ABT – Research Report), Adagene (ADAG – Research Report) and Teleflex (TFX – Research Report).
Abbott Labs (ABT)
TD Cowen analyst Josh Jennings maintained a Buy rating on Abbott Labs on January 17 and set a price target of $130.00. The company’s shares closed last Monday at $114.64, close to its 52-week high of $115.83.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
Currently, the analyst consensus on Abbott Labs is a Strong Buy with an average price target of $127.75, representing an 11.2% upside. In a report issued on January 3, BTIG also maintained a Buy rating on the stock with a $135.00 price target.
See the top stocks recommended by analysts >>
Adagene (ADAG)
H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Adagene on January 17 and set a price target of $5.00. The company’s shares closed last Monday at $2.50.
According to TipRanks.com, CFA is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adagene with a $4.60 average price target, which is a 73.6% upside from current levels. In a report issued on January 17, Morgan Stanley also maintained a Buy rating on the stock with a $4.60 price target.
Teleflex (TFX)
Needham analyst Michael Matson maintained a Hold rating on Teleflex on January 17. The company’s shares closed last Monday at $251.81.
According to TipRanks.com, Matson is a 1-star analyst with an average return of
Currently, the analyst consensus on Teleflex is a Moderate Buy with an average price target of $266.86, representing a 7.8% upside. In a report issued on January 16, Piper Sandler also assigned a Hold rating to the stock with a $280.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABT:
- Options Volatility and Implied Earnings Moves This Week, January 22 – January 26, 2024
- Abbott Laboratories (ABT) Q4 Earnings Cheat Sheet
- Abbott announces first procedures using its Volt Pulsed Field Ablation
- Abbott price target raised to $131 from $121 at Wells Fargo
- Abbott price target raised to $128 from $119 at RBC Capital
